tbuckley/cabot-search huggingface dataset:
Abstract 3674: MIG-6 suppresses epithelial cell proliferation via inhibiting AKT phosphorylation during endometrial tumorigenesis
Authors: Tae Hoon Kim, Jung-Yoon Yoo, Jae Hee Lee, Byung Gak Kim, Russell R. Broaddus, Jae-Wook Jeong
Journal: Cancer Research (2016)

Abstract Endometrial cancer is the most frequently diagnosed malignancy of the female genital tract. Hysterectomy is typically the first line therapeutic strategy for endometrial cancer. However, there is an increasing demand for nonsurgical approaches for endometrial cancer, especially for women of reproductive age with endometrial cancer who wish to preserve their fertility. Most endometrial cancers are characterized by actively proliferating epithelial cells, increased AKT signaling and association with prolonged, unopposed E2 exposure. Mitogen-inducible gene 6 (Mig-6) is an important mediator of progesterone receptor action in the murine uterus. As P4 achieves the inhibition of proliferation by coordinating stromal-epithelial cross-talk, we generated a mouse model in which we specifically ablate epithelial endometrial Mig-6 using Sprr2f-cre mice (Sprr2fcre+Mig-6f/f) to understand the role of epithelial Mig-6 in the uterus. Sprr2fcre+Mig-6f/f mice displayed endometrial hyperplasia upon 10 weeks of age and develop endometrial cancer by E2 treatment for 3 months. The levels of epithelial proliferation by Ki67 staining were significantly increased in epithelial cells of Sprr2fcre+Mig-6f/f mice at 10 weeks of age. The levels of phospho-AKT and phospho-S6, downstream of AKT, were remarkably higher in Sprr2fcre+Mig-6f/f mice. Interestingly, the hyperplasia exhibited by Sprr2fcre+Mig-6f/f mice was prevented by P4 treatment for 1 week in morphological and histological analysis. Aberrant activation of proliferation as well as AKT signaling was decreased in the epithelium of Sprr2fcre+Mig-6f/f mice by P4 treatment. Furthermore, we identified that MIG-6 inhibits AKT phosphorylation in human endometrial cancer cells. These data suggest that stromal P4 signaling including Mig-6 is critical in regulation of epithelial cell proliferation via regulating AKT phosphorylation during endometrial cancer development and progression. (This work was supported by American Cancer Society Research Grant, RSG-12-084-01-TBG to J.W.J.) Citation Format: Tae Hoon Kim, Jung-Yoon Yoo, Jae Hee Lee, Byung Gak Kim, Russell R. Broaddus, Jae-Wook Jeong. MIG-6 suppresses epithelial cell proliferation via inhibiting AKT phosphorylation during endometrial tumorigenesis. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3674.
Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis
Authors: F. Nolè, R. Iacovelli, E. Verri, G. Renne, C. Paglino, M. Santoni, M. Cossu Rocca, P. Giglione, G. Aurilio, D. Cullurà, S. Cascinu, C. Porta
Journal: Annals of Oncology (2015)
Abstract 3235: IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligands
Authors: Aparna Rao, Xiaoran Zhang, Christopher Deibert, Paola Sette, Tim Chan, Paola Grandi, Nduka Amankulor
Journal: Cancer Research (2016)

Abstract Background: Diffuse gliomas are fatal primary brain tumors that are poorly immunogenic. The basis for insufficient anti-tumor immunity in diffuse gliomas is not understood. Gain of function mutations in isocitrate dehydrogenases (IDH1 and IDH2) promote diffuse glioma formation through epigenetic reprogramming of a number of genes, including immune-related genes. Here, we identify epigenetic dysregulation of natural killer (NK) cell ligand genes as significant contributors to immune escape in glioma. Methods: We analyzed the TCGA database for immune gene expression patterns in IDH mutant or wild-type gliomas and identified differentially expressed immune genes. NKG2D ligands expression levels and NK cell-mediated lysis were measured in IDH mutant and wild-type patient-derived glioma stem cells and in genetically engineered astrocytes. Finally, we assessed the impact of hypomethylating agent 5-aza- 2’deoxycytodine (Decitabine) as a potential NK cell sensitizing agent in IDH mutant cells. Results: All IDH mutant glioma stem-like cell lines exhibited significantly lower expression of NKG2D ligands compared with IDH wild-type cells. Consistent with these findings, IDH mutant glioma cells and astrocytes were resistant to NK cell- mediated lysis. The hypomethylating agent Decitabine increased NKG2D ligand expression, and restored NK-mediated lysis of IDH mutant cells in an NKG2D- dependent manner. Conclusions: IDH mutant glioma cells acquire resistance to NK cells through epigenetic silencing of NKG2D ligands ULBP1 and ULPB3. Decitabine-mediated hypomethylation restores ULBP1 and ULBP3 expression in IDH mutant glioma cells and may provide a clinically useful method to sensitize IDH mutant gliomas to NK cell- mediated immune surveillance in patients with IDH mutated diffuse gliomas. Citation Format: Aparna Rao, Xiaoran Zhang, Christopher Deibert, Paola Sette, Tim Chan, Paola Grandi, Nduka Amankulor. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligands. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3235.
Abstract 3844: A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects
Authors: Chiara Brignole, Patrizia Perri, Francesca Piaggio, Fabio Pastorino, Daniela Di Paolo, Laura Emionite, Antonio Daga, Vangelis Kondylis, Manolis Pasparakis, Domenico Ribatti, Mirco Ponzoni
Journal: Cancer Research (2016)

Abstract The depletion of tumor-associated macrophages (TAMs), involved in different stages of cancer development and progression, is an appealing strategy in cancer therapy. We developed novel Clodronate-containing liposomes (Clo-Lipo-DOTAP) presenting good physicochemical properties (size distribution, polidispersity index and Z-potential). In vitro, Clo-Lipo-DOTAP inhibited proliferation, reduced viability and induced apoptosis of a macrophage-like cell line in a dose- and time-dependent manner. In proof of functionality experiments, Clo-Lipo-DOTAP depleted macrophages in a genetic mouse model of chronic hepatitis and hepatocellular carcinoma leading to a significant reduction of F4/80-positive cells in the liver and spleen of treated mice compared to PBS-treated controls. The number of granulocytes, B and T lymphocytes was not affected. In B16/F10 subcutaneous melanoma-bearing mice, Clo-Lipo-DOTAP significantly reduced the volume of primary tumors (P &amp;lt; 0.001). Within the tumors, the expression F4/80 and α-SMA was significantly lowered. Plasma levels of IL-10, Mo KC, TNF-α, VEGF and PDGF-bb were statistically decreased. In B16/F10 lung metastatic melanoma model, treatment with Clo-Lipo-DOTAP significantly reduced the number of pulmonary nodules (P &amp;lt; 0.05). F4/80-positive cells and microvessel density were statistically decreased. In conclusion, the depletion of TAMs in primary and metastatic melanoma presents anti-tumor efficacy via inhibition of angiogenesis and modulation of inflammation related cytokines. Citation Format: Chiara Brignole, Patrizia Perri, Francesca Piaggio, Fabio Pastorino, Daniela Di Paolo, Laura Emionite, Antonio Daga, Vangelis Kondylis, Manolis Pasparakis, Domenico Ribatti, Mirco Ponzoni. A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3844.
Abstract 501: PD-L1 expressing circulating tumor cells (CTCs) in patients with breast cancer
Authors: Martha Zavridou, Areti Strati, Nikos Malamos, Vasilis Georgoulias, Evi S. Lianidou
Journal: Cancer Research (2016)

Abstract Background: Programmed cell Death receptor Ligand 1 (PD-L1) is a very promising biomarker for the selection of patients for cancer immunotherapy. We recently developed a highly sensitive, specific and robust RT-qPCR assay for PD-L1 mRNA. The aim of the present study was to study the expression of PD-L1 in CTCs from breast cancer patients with verified metastasis. Methods: We quantified the expression of PD-L1 mRNA transcripts in EpCAM-positive CTCs, by using our recently developed RT-qPCR assay, based on the following procedure: i) immunomagnetic enrichment of EpCAM-positive CTCs from 20mL of peripheral blood, ii) total RNA isolation iii) cDNA synthesis and iv) RT-qPCR for PD-L1. PD-L1 expression in respect to the expression of B2M as a reference gene, was normalized using the 2-ΔΔCt approach. Peripheral blood samples (20mL) were obtained from 22 breast cancer patients with verified metastasis and 14 healthy donors. Results: According to our results, 11/22 (50%) of metastasis-verified breast cancer patients were found to be positive for PD-L1 overexpression in CTCs. These are preliminary results and these percentages may change, since the number of samples that we are analyzing is continuously increasing. Our results are in concordance with a recent study by Mazel et al (Mol Oncol 2015), that by using the CellSearch(®) system found PD-L1((+)) CTCs in 11/16(68.8%) patients with metastatic breast cancer. Conclusion: This is the first time that a quantitative RT-qPCR molecular assay is used for the evaluation of PD-L1expression levels in EpCAM-positive CTCs in metastatic breast cancer patients. The assay is closed-tube, quantitative, highly specific and sensitive, and high-throughput. We are currently evaluating the assay in a large number of clinical samples. Citation Format: Martha Zavridou, Areti Strati, Nikos Malamos, Vasilis Georgoulias, Evi S. Lianidou. PD-L1 expressing circulating tumor cells (CTCs) in patients with breast cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 501.
Safety and efficacy of the CD95-ligand inhibitor APG101 in transfusion-dependent patients with low risk MDS: Interim results from a phase I study.
Authors: Tobias Boch, Wolf-Karsten Hofmann, Claudia Kunz, Harald Fricke, Thomas Luft, Max Mossner, Johann Christoph Jann, Daniel Nowak, Christine Folz, Jennifer Klemmer, Susanne Brendel, Anthony D. Ho, Florian Nolte
Journal: Journal of Clinical Oncology (2016)

e18552 Background: Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis resulting in peripheral cytopenia. In low risk MDS, a pro-apoptotic milieu was found with increased levels of apoptosis-promoting factors (e.g. CD95L) resulting in increased apoptosis of erythroid progenitors and peripheral cytopenia. APG101 is a fusion protein consisting of the extracellular domain of human CD95 and the Fc part of human IgG1. By binding to CD95L, it inhibits the activation of CD95. Here, we report interim results of a phase I study in transfusion-dependent low or intermediate risk MDS patients treated with APG101. Methods: Results are based on data from 14 of 20 patients which gave written informed consent. The study was performed according to ICH-GCP and approved by IRB and Authorities. Patients were treated for 12 weeks with weekly i.v. infusions of 100 mg (6 patients) or 400 mg APG101 (8 patients). Thereafter, they were followed for 6 months. Bone marrow (BM) biopsies were taken predose, at end of treatment, week 25 and week 37 (follow up) and were subject to cytologic, cytogenetic, molecular and immunophenotypic analyses. Methylcellulose assays on isolated CD34+ cells from BM aspirates were performed as well as amplicon deep sequencing to detect gene mutations. Results: WPSS was low (2 patients) and intermediate (12 patients); medullary blast count was ‹5%. Evaluation of BM smears as well as immune phenotypic analysis showed no increase in blasts. Quantification of the allele burden of pre-existing mutations showed no expansion of mutated clones. Ex vivodifferentiation analyses revealed an increase in CFU-E/BFU-E forming capacity as well as granulocytic colony forming. 5 of 14 patients showed a significant decrease in transfusion frequency, 1 patient became transfusion-free. Conclusions: APG101 was tolerated very well. No patient discontinued treatment. Deep amplicon sequencing did not show any signs of expansion of preexisting clones during therapy. Major and minor hematologic improvement was seen in 4 (major) and 1 (minor) of the patients, one patient became transfusion-free. Therefore, APG101 is an interesting target for further investigation. Clinical trial information: NCT01736436.
Abstract 3240: Prostate cancer exosomes and their effects on macrophage engulfment and polarization
Authors: Evita G. Weagel, Wei Meng, Richard A. Robison, Kim L. O’Neill.
Journal: Cancer Research (2016)

Abstract The purpose of this study is to explore the effects of prostate cancer-derived exosomes on macrophage engulfment and polarization. Exosomes are small vesicles secreted by virtually all cells, which contain nucleic acids, lipids, proteins, and carbohydrates. Exosomes can be abundantly found in cancer patient secretions (serum, urine, etc.) and contain a high amount of RNA molecules, some of them being miRNA, and parts of the DNA of the cell of origin. One of the functions of exosomes is to mediate cellular communication. This occurs as they are secreted from one cell and then distribute their contents into other cells. Some exosomes specifically target immune cells. The miRNA the exosomes carry can silence genes involved in the activation of these immune cells, leading to immune suppression and tumor growth. Macrophages are often found surrounding the tumor microenvironment, as they are recruited by tumor signals to promote angiogenesis and metastasis. These macrophages, which are often called tumor associated macrophages (TAMs), are exposed to various signals derived from the tumor microenvironment, including exosomes. Previous data generated in our lab suggests that the co-culture of macrophages with PC3 and DU145 cell lines results in a decrease in macrophage phagocytosis and an M2-like polarization state. For this study, we exposed U937 cells to phorbol 12-myristate 13-acetate (PMA) for 24 hours to allow for differentiation. Then, we co-cultured these macrophages with isolated exosomes from spent media from both PC3 and DU145 cell lines at 1, 2, 3, 4, 5, 6, 12, and 24 hours. We then allowed the macrophages to phagocytose fluorescent microbeads for 1 hour. Flow cytometry analysis of these macrophages revealed that the total bead phagocytosis starts decreasing at 3 hours of exosome co-culture compared to control. Interestingly, total bead phagocytosis resumes to normal at 12 and 24 hours of exosome co-culture. Gene expression analysis of these macrophages suggests an M2 phenotype from hours 2-24. These results suggest that prostate cancer-derived exosomes can target macrophages and affect their phagocytosis. Further research is required to elucidate the specific genes these exosomes target. Citation Format: Evita G. Weagel, Wei Meng, Richard A. Robison, Kim L. O’Neill. Prostate cancer exosomes and their effects on macrophage engulfment and polarization. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3240.
Abstract 2736: Regulation of cytokinesis by polo-like kinase 4
Authors: Michael F. Press, Bin Xie, Simon Davenport, Yu Zhou, Neil O’Brien, Michael Palazzolo, Tak Mak, Joan Brugge, Dennis J. Slamon
Journal: Cancer Research (2016)

Abstract Introduction. The serine/threonine mitotic kinase, polo-like kinase 4 (PLK4), is known to play a critical role in centrosome duplication in preparation for cell division. Based on our preliminary observations with a PLK4 kinase inhibitor, we investigated the possibility that PLK4 may also play a role in regulation of cytokinesis. Experimental Procedures. Immunofluorescence was used to localize PLK4 and phospho-PLK4 in cultured human breast, ovarian, and colorectal cancer cell lines throughout the cell cycle without and with CFI-400945 PLK4 inhibitor and MG-115 protease inhibitor. Flow cytometry and videomicroscopy were used to analyze the consequences of PLK4 inhibition on cytokinesis. Results. Using immunofluorescence, PLK4 was localized to centrosomes; however, we also found that phospho-PLK4 was cleaved and distributed to kinetochores (metaphase and anaphase), cleavage furrow (telophase), and middle body (cytokinesis) during cell division in colorectal, ovarian, and breast cancer cells. Distribution of phospho-PLK4 to the cleavage furrow and middle body raised the possibility that this kinase plays a functional role in cytokinesis. Using either CFI-400945 PLK4 kinase inhibitor or the MG-115 protease inhibitor, we found that PLK4 accumulated in centrosomes with inhibition of translocation of PLK4 to the middle body. This change in subcellular distribution of PLK4 was associated with generation of large, multi-nucleated tumor cells or tumor cells with polyploidy. Videomicroscopy confirmed that treatment with CFI-400945 PLK4 inhibitor was associated with prevention of cellular abscission in treated cells. Conclusions. These observations demonstrate a role for phospho-PLK4 in facilitation of cytokinesis. A regulatory role for PLK4 in cytokinesis makes it a potential target for therapeutic intervention in appropriately selected cancers. Citation Format: Michael F. Press, Bin Xie, Simon Davenport, Yu Zhou, Neil O’Brien, Michael Palazzolo, Tak Mak, Joan Brugge, Dennis J. Slamon. Regulation of cytokinesis by polo-like kinase 4. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2736.
Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission — United States and Kentucky, 2011–2014
Authors: Alaya Koneru, Noele Nelson, Susan Hariri, Lauren Canary, Kathy J. Sanders, Justine F. Maxwell, Xiaohua Huang, John A.D. Leake, John W. Ward, Claudia Vellozzi
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Hepatitis C virus (HCV) infection is a leading cause of liver-related morbidity and mortality (1). Transmission of HCV is primarily via parenteral blood exposure, and HCV can be transmitted vertically from mother to child. Vertical transmission occurs in 5.8% (95% confidence interval = 4.2%-7.8%) of infants born to women who are infected only with HCV and in up to twice as many infants born to women who are also infected with human immunodeficiency virus (HIV) (2) or who have high HCV viral loads (3,4); there is currently no recommended intervention to prevent transmission of infection from mother to child (3). Increased reported incidence of HCV infection among persons aged ≤30 years (5,6) with similar increases among women and men in this age group (6), raises concern about increases in the number of pregnant women with HCV infection, and in the number of infants who could be exposed to HCV at birth. Data from one large commercial laboratory and birth certificate data were used to investigate trends in HCV detection among women of childbearing age,* HCV testing among children aged ≤2 years, and the proportions of infants born to HCV-infected women nationally and in Kentucky, the state with the highest incidence of acute HCV infection during 2011-2014 (6). During 2011-2014, commercial laboratory data indicated that national rates of HCV detection (antibody or RNA positivity(†)) among women of childbearing age increased 22%, and HCV testing (antibody or RNA) among children aged ≤2 years increased 14%; birth certificate data indicated that the proportion of infants born to HCV-infected mothers increased 68%, from 0.19% to 0.32%. During the same time in Kentucky, the HCV detection rate among women of childbearing age increased >200%, HCV testing among children aged ≤2 years increased 151%, and the proportion of infants born to HCV-infected women increased 124%, from 0.71% to 1.59%. Increases in the rate of HCV detection among women of childbearing age suggest a potential risk for vertical transmission of HCV. These findings highlight the importance of following current CDC recommendations to identify, counsel, and test persons at risk for HCV infection (1,7), including pregnant women, as well as consider developing public health policies for routine HCV testing of pregnant women, and expanding current policies for testing and monitoring children born to HCV-infected women. Expansion of HCV reporting and surveillance requirements will enhance case identification and prevention strategies.
Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide Hydroxamic Acid, SAHA), in Patients with Leukemia and Myelodysplastic Syndrome.
Authors: Guillermo Garcia-Manero, Hui Yang, Blanca Sanchez-Gonzalez, Srdan Verstovsek, Alessandra Ferrajoli, Michael Keating, Michael Andreeff, Susan O’Brien, Jorge Cortes, William Wierda, Stefan Faderl, Charles Koller, Jan Davis, Gail Morris, Jean-Pierre Issa, Stanley R. Frankel, Victoria Richon, Bernard Fine, Hagop Kantarjian
Journal: Blood (2005)
High-Dose Pomalidomide and Dexamethasone Induce Rapid Responses In Patients With AL Amyloidosis Exposed To Alkylators, Immune Modulatory Drugs, and Proteasome Inhibitors
Authors: Giovanni Palladini, Paolo Milani, Marta Vidus Rosin, Andrea Foli, Giampaolo Merlini
Journal: Blood (2013)